Seeking Alpha

Amarin (AMRN) has been issued a patent by the USPTO covering the pharmaceutical composition of...

Amarin (AMRN) has been issued a patent by the USPTO covering the pharmaceutical composition of the company's Vascepa capsules. Vascepa has already been approved by the FDA for the treatment of high levels of triglycerides, and the company plans to list the patent in the FDA's Orange Book.
Comments (3)
  • fishpimp
    , contributor
    Comment (1) | Send Message
     
    waiting for the NCE. Give it to them!!!
    30 Oct 2012, 10:16 PM Reply Like
  • brendoo7
    , contributor
    Comments (8) | Send Message
     
    the NCE is on the way for amarin.and the share going to bee 14.5 soon after thay get the NCE.. AMARIN is a very smart company.with a very good management.MR JOSEPH S ZAKRZEWSKI. already sales lovaza
    to GSK wich is a similar drug.but VASEPA is much better is going to do that again if you are investor you should not bee listening for all of the speculative around the company by speculative analyst you can bee sure that all thay want is to buy your shares in good price.dont let them do this to you.bee strong and hapy'''''
    31 Oct 2012, 12:36 PM Reply Like
  • Donegal17
    , contributor
    Comments (2) | Send Message
     
    What is the significance of the patent by the USPTO.and who is theUSPTO?
    31 Oct 2012, 01:48 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|